USES OF SIGLEC-9 ECD FUSION MOLECULES IN CANCER TREATMENT

The present disclosure relates to methods of treating certain cancers with a Siglec-9 extracellular domain (ECD) or a Siglec-9 ECD fusion molecule, including cancers expressing high levels of CD163 and/or Siglec-9 in tumor or immune cells, and methods of identifying cancers responsive to a Siglec-9...

Full description

Saved in:
Bibliographic Details
Main Authors LIANG, Spencer, NALLE, Samuel
Format Patent
LanguageEnglish
French
Published 16.05.2024
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to methods of treating certain cancers with a Siglec-9 extracellular domain (ECD) or a Siglec-9 ECD fusion molecule, including cancers expressing high levels of CD163 and/or Siglec-9 in tumor or immune cells, and methods of identifying cancers responsive to a Siglec-9 ECD or Siglec-9 ECD fusion molecule, for example by determining the level of CD163 and/or Siglec-9, and in some embodiments also CD68 and/or sialic acid expression in tumor or immune cells. La présente invention concerne des méthodes de traitement de certains cancers avec un domaine extracellulaire Siglec-9 (ECD) ou une molécule de fusion Siglec-9 ECD, comprenant des cancers exprimant des niveaux élevés de CD163 et/ou de Siglec-9 dans des cellules tumorales ou immunitaires, et des méthodes d'identification de cancers sensibles à Siglec-9 ECD ou une molécule de fusion Siglec-9 ECD, par exemple en déterminant le niveau de CD163 et/ou de Siglec-9, et dans certains modes de réalisation également l'expression de CD68 et/ou d'acide sialique dans des cellules tumorales ou immunitaires.
Bibliography:Application Number: WO2023US78776